ArrowArtboardCreated with Sketch.Title ChevronTitle ChevronIcon FacebookIcon LinkedinIcon Mail ContactPath LayerIcon MailPositive ArrowIcon PrintIcon Twitter

Pfizer vaccine hopes give Asia markets a shot in the arm

Developers report initial 'success' but analysts warn of long rollout

A sign with the Pfizer logo stands outside the corporate headquarters of Pfizer Canada in Montreal on Nov. 9.   © AP

TOKYO/NEW YORK -- Investors in Asian markets snapped up pandemic-hit stocks on Tuesday on hopes of a breakthrough against COVID-19 after drugmaker Pfizer indicated its candidate vaccine had proved more than 90% effective in its most widespread trial.

Japan's equity benchmark Nikkei Stock Average at one point surged over 400 points, or 1.7%, on Tuesday morning, reaching the 25,000 threshold for the first time in 29 years. The broader Topix also jumped over 1% and reached its highest point in nine months.

The Nikkei lost steam during afternoon trade and closed up 0.2%. Tuesday marks the benchmark's sixth straight day of gains -- it has risen more than 1,000 points since the end of last month. 

Other Asian markets also rose, with Australia's equity benchmark and South Korea's Kospi climbing slightly while the Hang Seng Index in Hong Kong climbed 1%.

Investors took the chance to load up on shares in companies that have been hit hard by the pandemic, such as airlines. Japan's ANA Holdings closed up 18% while in Hong Kong Cathay Pacific Airways and Singapore Airlines both climbed 13%.

Shares in other travel-related companies also rose, including West Japan Railway and East Japan Railway, which rose 15%.

Meanwhile, shares in companies that have benefited from the pandemic, such as entertainment businesses, took a dive. Nintendo shares fell over 4% while Sony's stock price dropped over 3%. Tencent Holdings saw its share price fall over 4%. 

The improved outlook for oil prices lifted CNOOC 13% and PetroChina by 4.3%. Meanwhile HSBC shares jumped 5.7% on hopes that a vaccine will allow the bank to cut bad debt provisions and boost interest income.

China's CSI 300 Index of the biggest shares traded in Shanghai and Shenzhen, fell 0.6% in afternoon trade. The index had risen for six consecutive sessions gaining from the recovery across the second largest economy, which has managed to control the pandemic. Analysts said investors were taking gains and deploying the cash in beaten down cyclical stocks across the region.

The generally bullish sentiment followed news from U.S.-based Pfizer and German partner BioNTech that their vaccine candidate "demonstrated evidence of efficacy against COVID-19 in participants without prior evidence of SARS-CoV-2 infection."

Ray Attrill, strategist at National Australia Bank in Sydney, said: "My fellow market analysts at NAB and BNZ (Bank of New Zealand) have often remarked that no-one wants to be short equities the day that a successful coronavirus vaccine is announced. Well, we may just have arrived at the day."

Tai Hui, Chief Asia Market Strategist, J.P. Morgan Asset Management in Hong Kong, said: "The market reaction overnight reinforces our asset allocation views in the next 6-12 months, as the global economy gradually recovers from the pandemic. A medical solution could potentially accelerate this rebound."

"The vaccine, and higher bond yields, are important catalysts for a rotation towards the pandemic laggards, such as consumer discretionary, travel, energy and commodities and financials sectors."

The Dow Jones Industrial Average closed in the U.S. on Monday with a gain of 834 points, or nearly 3%, at 29,157, having risen as much as 1,600 points at the start of trading.

While the benchmark index set a new intraday record and flirted with 30,000, momentum faded as the session went on. The broader S&P 500 index closed with a modest 1% gain.

The New York Stock Exchange: The Dow Jones Industrial Average opened within reach of 30,000 on Nov. 9.   © Reuters

The announcement raised hopes of light at the end of the tunnel for the U.S. economy as COVID-19 cases mount. Pfizer and BioNTech reported that the experimental vaccine was shown to be more than 90% effective, a level that Citi Healthcare analysts said "exceeds the most optimistic market expectations."

Morgan Stanley said it expects "strong Moderna data in the near term as well" for the U.S. biotech company's trials of its own COVID-19 vaccine candidate.

But others warned against hoping that a vaccine will stop the coronavirus in its tracks soon.

"Even based on the most optimistic estimates, the Pfizer vaccine will not be rolled out fast enough for large parts of the population to avoid a winter 2020-21 Wave 2," said Andrew Bishop, global head of policy research at Signum Global Advisors.

U.K. Prime Minister Boris Johnson, a COVID-19 survivor, echoed this caution.

"I just don't want to let people run away with the idea that this development today is necessarily a home run, a slam dunk, a shot to the back of the net yet," Johnson told reporters, adding that "there's a long way, I'm afraid, until we've got this thing beat."

Investors also were emboldened to take on risk by Democratic candidate Joe Biden securing enough electoral votes to win the U.S. presidency, easing uncertainty over last week's election outcome.

Biden urged Americans to take precautions.

"We could save tens of thousands of lives if everyone would just wear a mask for the next few months," he said.

The Federal Reserve in its Financial Stability Report released Monday warned that markets could still take a hit if the economic impact from coronavirus pandemic worsens in the coming months.

While most assets have remained elevated thanks to government support, signs of weakness are emerging in sectors such as commercial real estate, the report said.

"Uncertainty remains high, and investor risk sentiment could shift swiftly should the economic recovery prove less promising or progress on containing the virus disappoint," the Fed said.

Additional reporting by Narayanan Somasundaram in Hong Kong

Sponsored Content

About Sponsored Content This content was commissioned by Nikkei's Global Business Bureau.

You have {{numberArticlesLeft}} free article{{numberArticlesLeft-plural}} left this monthThis is your last free article this month

Stay ahead with our exclusives on Asia;
the most dynamic market in the world.

Stay ahead with our exclusives on Asia

Get trusted insights from experts within Asia itself.

Get trusted insights from experts
within Asia itself.

Try 1 month for $0.99

You have {{numberArticlesLeft}} free article{{numberArticlesLeft-plural}} left this month

This is your last free article this month

Stay ahead with our exclusives on Asia; the most
dynamic market in the world

Get trusted insights from experts
within Asia itself.

Try 3 months for $9

Offer ends July 31st

Your trial period has expired

You need a subscription to...

  • Read all stories with unlimited access
  • Use our mobile and tablet apps
See all offers and subscribe

Your full access to Nikkei Asia has expired

You need a subscription to:

  • Read all stories with unlimited access
  • Use our mobile and tablet apps
See all offers
NAR on print phone, device, and tablet media

Nikkei Asian Review, now known as Nikkei Asia, will be the voice of the Asian Century.

Celebrate our next chapter
Free access for everyone - Sep. 30

Find out more